‘All it takes is a post on Truth Social’: Is this patent reform's moment?

A US Senate subcommittee hearing on patent eligibility reform has David Kappos, former USPTO director, believing that “there’s a better chance than ever” of a pending bill becoming law, finds Sarah Speight.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Mylan withdraws defence claims against Novo in Wegovy dispute

13 March 2026 A proposed judgment by the rivals would extend the period in which Mylan is barred from obtaining regulatory approval for its generic of the weight-loss injectable.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

Americas

Astellas blocks generic version of key urology drug until 2030

12 March 2026 The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.

More features

Mylan withdraws defence claims against Novo in Wegovy dispute

INTA: ‘New normal’ for in-house counsel as budgets fall

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

GSK inks licensing deal for liver disease drug

Arnold & Porter adds tech litigator in San Francisco

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

‘All it takes is a post on Truth Social’: Is this patent reform's moment?

More on this story

Editor's picks

Editor's picks

More features